Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination

Gross, Lise; Lhomme, Édouard; Pasin, Chloé; Richert, Laura; Thiébaut, Rodolphe

doi:10.1016/j.ijid.2018.06.022

Cited by 25 publications

(16 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A first meta-analysis has now been published by Gross and colleagues summarizing antibody responses of all clinical trials in which VSV-EBOV was tested. 68 All studies observed induction of EBOV GP-specific antibody responses following immunization with VSV. Antibody responses developed at 14 days p.v., peaked around day 28 and remained detectable for at least 2 years.…”

Section: Correlates Of Protection and Duration Of Immune Responsesmentioning

confidence: 99%

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Fathi

Dahlke

Addo

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens. ARTICLE HISTORY

show abstract

Section: Correlates Of Protection and Duration Of Immune Responsesmentioning

confidence: 99%

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Fathi

Dahlke

Addo

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…To do this, we can start by doing a simple search in PubMed or Google Scholar with search terms Ebola AND vaccine. While doing this step, we identify a systematic review and meta-analysis of determinant factors influencing antibody response from vaccination of Ebola vaccine in non-human primate and human [7], which is a relevant paper to read to get a deeper insight and identify gaps for better formulation of our research question or purpose. We can still conduct systematic review and meta-analysis of Ebola vaccine because we evaluate safety as a different outcome and different population (only human).…”

Section: Preliminary Research and Idea Validationmentioning

confidence: 99%

A step by step guide for conducting a systematic review and meta-analysis with simulation data

Dila²,

et al. 2019

View full text Add to dashboard Cite

Background The massive abundance of studies relating to tropical medicine and health has increased strikingly over the last few decades. In the field of tropical medicine and health, a well-conducted systematic review and meta-analysis (SR/MA) is considered a feasible solution for keeping clinicians abreast of current evidence-based medicine. Understanding of SR/MA steps is of paramount importance for its conduction. It is not easy to be done as there are obstacles that could face the researcher. To solve those hindrances, this methodology study aimed to provide a step-by-step approach mainly for beginners and junior researchers, in the field of tropical medicine and other health care fields, on how to properly conduct a SR/MA, in which all the steps here depicts our experience and expertise combined with the already well-known and accepted international guidance. We suggest that all steps of SR/MA should be done independently by 2–3 reviewers’ discussion, to ensure data quality and accuracy. Conclusion SR/MA steps include the development of research question, forming criteria, search strategy, searching databases, protocol registration, title, abstract, full-text screening, manual searching, extracting data, quality assessment, data checking, statistical analysis, double data checking, and manuscript writing. Electronic supplementary material The online version of this article (10.1186/s41182-019-0165-6) contains supplementary material, which is available to authorized users.

show abstract

“…EBOV-specific humoral immune responses are likely necessary for protection from severe disease and most studies measure antibodies that bind the EBOV glycoprotein (GP) as the primary marker for immunogenicity ( 13 ) and as surrogate for vaccine efficacy according to the animal rule ( 14 ), a process by which animal study can replace human efficacy trials when they are not feasible or ethical. A follow up study of the 100% efficacious rVSV-EBOV found that the majority of vaccinated subjects maintained EBOV specific antibodies two years after vaccination ( 15 ).…”

Section: Introductionmentioning

confidence: 99%

Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors

et al. 2021

View full text Add to dashboard Cite

Antibodies that mediate non-neutralizing functions play an important role in the immune response to Ebola virus (EBOV) and are thought to impact disease outcome. EBOV has also been associated with long term sequelae in survivors, however, the extent to which antibodies that mediate non-neutralizing functions are associated with the development of these sequelae is unknown. Here, the presence of antibodies mediating different effector functions and how they relate to long-term sequelae two years after the 2007 Bundibugyo Ebola virus (BDBV) outbreak was investigated. The majority of survivors demonstrated robust antibody effector functional activity and demonstrated persistent polyfunctional antibody profiles to the EBOV glycoprotein (GP) two years after infection. These functions were strongly associated with the levels of GP-specific IgG1. The odds of developing hearing loss, one of the more common sequelae to BDBV was reduced when antibodies mediating antibody dependent cellular phagocytosis (ADCP), antibody dependent complement deposition (ADCD), or activating NK cells (ADNKA) were observed. In addition, hearing loss was associated with increased levels of several pro-inflammatory cytokines and levels of these pro-inflammatory cytokines were associated with lower ADCP. These results are indicating that a skewed antibody profile and persistent inflammation may contribute to long term outcome in survivors of BDBV infection

show abstract

Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination

Cited by 25 publications

References 56 publications

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

A step by step guide for conducting a systematic review and meta-analysis with simulation data

Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors

Contact Info

Product

Resources

About